Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor

Yujie Zhao, Alex Adjei

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF/VEGFR signaling. Such approaches, however, often lead to transient responses and further diseaseprogression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/ PDGFR and FGF/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors.

Original languageEnglish (US)
Pages (from-to)660-673
Number of pages14
JournalOncologist
Volume20
Issue number6
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Platelet-Derived Growth Factor Receptors
Fibroblast Growth Factor Receptors
Neoplasms
Therapeutics
Vascular Endothelial Growth Factor Receptor-2
Fibroblast Growth Factors
Platelet-Derived Growth Factor
Human Development
Reproduction
Blood Vessels
Neoplasm Metastasis
Growth

Keywords

  • Angiogenesis inhibitors
  • Antibodies, monoclonal, humanized
  • Fibroblast growth factor
  • Molecular targeted therapy
  • Platelet-derived growth factor
  • Receptors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting angiogenesis in cancer therapy : Moving beyond vascular endothelial growth factor. / Zhao, Yujie; Adjei, Alex.

In: Oncologist, Vol. 20, No. 6, 01.01.2015, p. 660-673.

Research output: Contribution to journalArticle

@article{d048d99d93a24674ada444867dfee40c,
title = "Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor",
abstract = "Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF/VEGFR signaling. Such approaches, however, often lead to transient responses and further diseaseprogression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/ PDGFR and FGF/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors.",
keywords = "Angiogenesis inhibitors, Antibodies, monoclonal, humanized, Fibroblast growth factor, Molecular targeted therapy, Platelet-derived growth factor, Receptors, Vascular endothelial growth factor",
author = "Yujie Zhao and Alex Adjei",
year = "2015",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2014-0465",
language = "English (US)",
volume = "20",
pages = "660--673",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Targeting angiogenesis in cancer therapy

T2 - Moving beyond vascular endothelial growth factor

AU - Zhao, Yujie

AU - Adjei, Alex

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF/VEGFR signaling. Such approaches, however, often lead to transient responses and further diseaseprogression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/ PDGFR and FGF/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors.

AB - Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF/VEGFR signaling. Such approaches, however, often lead to transient responses and further diseaseprogression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/ PDGFR and FGF/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors.

KW - Angiogenesis inhibitors

KW - Antibodies, monoclonal, humanized

KW - Fibroblast growth factor

KW - Molecular targeted therapy

KW - Platelet-derived growth factor

KW - Receptors

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84932616956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932616956&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0465

DO - 10.1634/theoncologist.2014-0465

M3 - Article

C2 - 26001391

AN - SCOPUS:84932616956

VL - 20

SP - 660

EP - 673

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 6

ER -